Product Code: ETC051368 | Publication Date: Jul 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The Indonesia gastrointestinal drugs market is projected to register a CAGR of 5.2% over theperiod (2020-2026). The increasing prevalence of GI diseases such as gastric ulcer Crohn`s disease irritable bowel syndrome and Helicobacter pylori infection are anticipated to boost theof this market. Additionally factors such as rising awareness about healthcare and growing expenditure on health care are expected to drive the demand for gastrointestinal drugs in Indonesia during the review period.
Factors driving itsinclude an increase in gastroenterology disorders among people due to unhealthy dietary habits and sedentary lifestyles; launch of new products; increased focus on clinical trials; presence of unmet needs in terms of treatment options available for GI diseases; availability accessibility of modernized diagnostic services devices; introduction implementation government initiatives like National Health Insurance Program (JKN) by Ministry Of Health - Republic Of Indonesia for making advanced treatments affordable. These factors will bolster up the overall marketduring 2020?2026.
High cost associated with novel therapies may restrain drug purchases from patients which is likely hamper overall market expansion overperiod. Moreover stringent regulatory guidelines followed by country?s Drug Control Authority might further challenge manufacturers efforts related to entry their products into global markets specifically Japan or China etc. putting brakes on potentialstreams.
Major players operating in Indonesia Gastrointestinal Drugs Market amongst them some are Abbott Laboratories Inc. AstraZeneca plcFerring Pharmaceuticals Inc. GlaxoSmithKline PlcMerck Co. Inc. Novartis AGPfizer Inc.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Indonesia Gastrointestinal Drugs Market Overview |
3.1 Indonesia Country Macro Economic Indicators |
3.2 Indonesia Gastrointestinal Drugs Market Revenues & Volume, 2020 & 2030F |
3.3 Indonesia Gastrointestinal Drugs Market - Industry Life Cycle |
3.4 Indonesia Gastrointestinal Drugs Market - Porter's Five Forces |
3.5 Indonesia Gastrointestinal Drugs Market Revenues & Volume Share, By Drug Category, 2020 & 2030F |
3.6 Indonesia Gastrointestinal Drugs Market Revenues & Volume Share, By Route of Administration, 2020 & 2030F |
3.7 Indonesia Gastrointestinal Drugs Market Revenues & Volume Share, By Distribution Channel, 2020 & 2030F |
3.8 Indonesia Gastrointestinal Drugs Market Revenues & Volume Share, By Disease Types, 2020 & 2030F |
4 Indonesia Gastrointestinal Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Indonesia Gastrointestinal Drugs Market Trends |
6 Indonesia Gastrointestinal Drugs Market, By Types |
6.1 Indonesia Gastrointestinal Drugs Market, By Drug Category |
6.1.1 Overview and Analysis |
6.1.2 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Drug Category, 2020-2030F |
6.1.3 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Antiemetic, 2020-2030F |
6.1.4 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Acid Neutralizers, 2020-2030F |
6.1.5 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Anti-inflammatory, 2020-2030F |
6.1.6 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Laxatives & Antidiarrheal, 2020-2030F |
6.1.7 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Others, 2020-2030F |
6.2 Indonesia Gastrointestinal Drugs Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Oral, 2020-2030F |
6.2.3 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Parenteral, 2020-2030F |
6.2.4 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Rectal, 2020-2030F |
6.3 Indonesia Gastrointestinal Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Retail Pharmacies, 2020-2030F |
6.3.3 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Online Pharmacies, 2020-2030F |
6.3.4 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Hospital Pharmacies, 2020-2030F |
6.4 Indonesia Gastrointestinal Drugs Market, By Disease Types |
6.4.1 Overview and Analysis |
6.4.2 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Inflammatory Bowel Diseases, 2020-2030F |
6.4.3 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Gastroesophageal Reflux Diseases, 2020-2030F |
6.4.4 Indonesia Gastrointestinal Drugs Market Revenues & Volume, By Others, 2020-2030F |
7 Indonesia Gastrointestinal Drugs Market Import-Export Trade Statistics |
7.1 Indonesia Gastrointestinal Drugs Market Export to Major Countries |
7.2 Indonesia Gastrointestinal Drugs Market Imports from Major Countries |
8 Indonesia Gastrointestinal Drugs Market Key Performance Indicators |
9 Indonesia Gastrointestinal Drugs Market - Opportunity Assessment |
9.1 Indonesia Gastrointestinal Drugs Market Opportunity Assessment, By Drug Category, 2020 & 2030F |
9.2 Indonesia Gastrointestinal Drugs Market Opportunity Assessment, By Route of Administration, 2020 & 2030F |
9.3 Indonesia Gastrointestinal Drugs Market Opportunity Assessment, By Distribution Channel, 2020 & 2030F |
9.4 Indonesia Gastrointestinal Drugs Market Opportunity Assessment, By Disease Types, 2020 & 2030F |
10 Indonesia Gastrointestinal Drugs Market - Competitive Landscape |
10.1 Indonesia Gastrointestinal Drugs Market Revenue Share, By Companies, 2023 |
10.2 Indonesia Gastrointestinal Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |